이지바이오
Financials
Valuation Metrics
이지바이오's Market Cap is ₩1737B. At end of 2025 it was ₩1922B. Ranked #886 of 2,405 in KR market (top 37%), #412 of 1,627 on KOSDAQ (top 25%), #32 of 82 in Food, Beverage & Tobacco (top 39%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 173.68B KRW | KR#886/2,405 Sec#32/82 |
| Revenue | 525.04B KRW | KR#606/2,405 Sec#37/82 |
| Net Income | 41.93B KRW | KR#476/2,405 Sec#20/82 |
| Total Assets | 385.93B KRW | KR#896/2,405 Sec#45/82 |
| Net Assets | 132.09B KRW | KR#1,213/2,405 Sec#52/82 |
| Employees | 134 | KR#1,407/2,405 Sec#55/82 |
| Value | ||
| P/E | 4.14x | KR#290/2,405 Sec#17/82 |
| P/B | 1.31x | KR#1,741/2,405 Sec#77/82 |
| PEG | 0.01x | KR#84/2,405 Sec#5/82 |
| P/S | 0.33x | KR#694/2,405 Sec#52/82 |
| EV/EBITDA | 5.67x | KR#316/2,405 Sec#15/82 |
| FCF Yield | 16.57% | KR#424/2,405 Sec#33/82 |
| Profitability | ||
| ROE | 31.74% | KR#53/2,405 Sec#1/82 |
| ROA | 10.86% | KR#234/2,405 Sec#3/82 |
| Op. Margin | 10.12% | KR#511/2,405 Sec#10/82 |
| Revenue Growth | 15.45% | KR#665/2,405 Sec#6/82 |
| Earnings Growth | 706.87% | KR#86/2,405 Sec#3/82 |
| Financial Health | ||
| Debt Ratio | 192.18% | KR#2,067/2,405 Sec#66/82 |
| Total Debt | 175.07B KRW | KR#551/2,405 Sec#33/82 |
| FCF | 28.78B KRW | KR#426/2,405 Sec#31/82 |
| Cash | 47.59B KRW | KR#761/2,405 Sec#35/82 |
| Current Ratio | 1.24x | KR#1,463/2,405 Sec#36/82 |
| Net Debt/EBITDA | 2.40x | KR#867/2,405 Sec#25/82 |
| Dividend | ||
| Div. Yield | 4.71% | KR#354/2,405 Sec#16/82 |
| Div. Growth | 25.00% | KR#390/2,405 Sec#17/82 |
| Performance | ||
| 1Y Return | -10.71% | KR#817/2,405 Sec#27/82 |
| 1M Return | -13.79% | KR#1,479/2,405 Sec#75/82 |
| From 52W High | -38.67% | KR#705/2,405 Sec#49/82 |
| 1Y MDD | -35.61% | KR#409/2,405 Sec#37/82 |
| Trading | ||
| Volume | 37,661 shares | KR#1,149/2,405 Sec#28/82 |
| Trading Value | 199.0M KRW | KR#1,129/2,405 Sec#29/82 |
| Foreign Own. | 5.55% | KR#785/2,405 Sec#28/82 |
| Per Share | ||
| EPS | 1,267 KRW | KR#626/2,405 Sec#26/82 |
| BPS | 3,993 KRW | KR#1,683/2,405 Sec#65/82 |
Company Info
Established in 2020 through a spin-off from Easy Holdings Co., Ltd., the company was re-listed on KOSDAQ in the same year. It specializes in manufacturing and selling animal pharmaceuticals, compound feed, and functional foods, alongside developing natural antimicrobial substances as antibiotic alternatives. The company differentiates its piglet feed with dedicated production facilities and processing technology, while developing high value-added feed additives based on fermentation engineering. Easy Bio was established in 2020 and is headquartered in Gangnam-gu, Seoul.